Targeting Inflammation in Atherosclerosis: CANTOS Trial
Targeting Inflammation in Atherosclerosis: CANTOS Trial

Average (ratings)
No ratings
 
  Your rating

Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US) provides us with an overview of the CANTOS main trial results and updated results from the ACC 2022.


Read MoreRead Less
Share

Supported by an unrestricted educational grant from NOVO NORDISK A/S.

Read MoreRead Less
Up Next
Targeting Inflammation in Atherosclerosis: RESCUE Trial
EP7 • Apr 12, 2022 • 4m 22s
Join Dr Peter Libby (Brigham and Women’s Hospital, Boston, US) as he talks us through the RESCUE trial design and results in this short podcast.
Read More
All Episodes
AI in Quantitative CT Assessments: CONFIRM2 with Dr Alexander Van Rosendael
EP38 • Nov 06, 2024 • 10m 30s
In this episode of the Innovations in Cardiology series, host Dr Dipti Itchhaporia is joined by Dr Alexander Van Rosendael to discuss the findings from the CONFIRM2 trial.
Read More
View from the Thoraxcenter: AHA 24 Late-breaking Preview
EP37 • Oct 29, 2024 • 13m 44s
Explore the cardiovascular breakthroughs shaping AHA 2024!

Join renowned experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they preview the most impactful late-breaking studies poised to make waves at this year’s AHA Conference.
Read More
Insights in Cardiovascular Innovation and Research
EP36 • Oct 14, 2024 • 21m 40s
Dr Dipti Itchhaporia, former president of the ACC, is joined by Dr C. Michael Gibson, CEO of the Baim Institute for Research, for an insightful discussion on the latest advancements and future directions in cardiovascular innovation for 2024.
Read More
Implementing AI Algorithms in Emergency Departments: RAPIDxAI with Dr Derek Chew
EP35 • Sep 30, 2024 • 18m 2s
Host, Dr Dipti Itchhaporia is joined by PI, Dr Derek Chew to discuss the findings from the RAPIDxAI trial, which aims to improve the assessment of suspected cardiac chest pain in emergency departments (ED) using a machine-learning algorithm that will interpret high-sensitivity troponin test results, assisting the diagnosis of myocardial infarction (MI) and other myocardial injuries.
Read More
AI and Digital Health in Cardiology
EP34 • Sep 13, 2024 • 27m 2s
In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia welcomes two leading experts in artificial intelligence in cardiology: Dr David Ouyang from Cedars-Sinai Medical Center in Los Angeles, and Dr Francisco Lopez-Jiminez from the Mayo Clinic in Rochester, MN.
Read More
View from the Thoraxcenter: EuroPCR 24 Preview
EP33 • May 07, 2024 • 26m 3s
Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC's Thoraxcenter for an insightful preview of the late-breaking science data to look out for at the 2024 EuroPCR meeting.
Read More
View from the Thoraxcenter: ACC.24 Wrap Up
EP32 • Apr 15, 2024 • 43m 48s
Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam for a deep dive into the late-breaking data presented at ACC.24.
Read More
ACC.24 Late-breaking Science Preview
EP31 • Mar 25, 2024 • 28m 10s
What’s hot at ACC.24?

Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.
Read More
VHPSD versus Conventional Catheter Ablation in AF
EP30 • Dec 14, 2023 • 29m 53s
In this episode of the Radcliffe Podcast, we are joined by Dr Raymond Pranata, Dr Mohammad Iqbal and Dr Giky Karwiky (Hasan Sadikin General Hospital, Bandung, Indonesia) as they discuss their recently published systematic review and meta-analysis of very-high-power short-duration ablation as compared to conventional ablation for the treatment of pulmonary vein isolation in atrial fibrillation.
Read More
View from the Thoraxcenter: AHA 23 Wrap Up
EP29 • Nov 20, 2023 • 23m 14s
Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the latest late-breaking science data from AHA Scientific Sessions 2023.
They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.
Read More
Targeting Inflammation in Atherosclerosis: LoDoCo2 Trial
EP8 • Apr 22, 2022 • 5m 3s
In this LoDoCo2 presentation, Dr Aernoud Fiolet (University Medical Center Utrecht, Netherlands) covers the trial design and main results.

Supported by an unrestricted educational grant from NOVO NORDISK A/S.

Read More
Targeting Inflammation in Atherosclerosis: RESCUE Trial
EP7 • Apr 12, 2022 • 4m 22s
Join Dr Peter Libby (Brigham and Women’s Hospital, Boston, US) as he talks us through the RESCUE trial design and results in this short podcast.
Read More
Targeting Inflammation in Atherosclerosis: CANTOS Trial
EP6 • Apr 12, 2022 • 6m 19s
Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US) provides us with an overview of the CANTOS main trial results and updated results from the ACC 2022.
Read More
Ep 5: Invasive Diagnosis of Coronary Functional Disorder
EP5 • Mar 25, 2022 • 29m 28s
Did you know that coronary vasomotion disorders are a frequent cause of angina in patients with non-obstructed coronary arteries? In this month's episode of the ECR podcast, Dr Andreas Seitz and Dr Peter Ong (Robert-Bosch Hospital, Stuttgart, DE) return to discuss their recent article on the diagnosis of coronary disorders which cause angina (https://www.ecrjournal.com/articles/invasive-diagnosis-coronary-functional-disorders-causing-angina-pectoris) from ECR Journal.
Read More
Ep 4: The EXCEL Trial: The Interventionalists’ Perspective
EP4 • Jan 28, 2022 • 12m 40s
In this month's featured author episode of the ECR Podcast, interventional fellow Dr George Hunter (Bedfordshire Hospitals NHS Foundation Trust, Bedford, UK) discusses the EXCEL trial from his perspective as a member of the PCI community, based on a recent review paper from the ECR Journal. In this podcast, Dr Hunter discusses the controversy surrounding the trial and the importance of studying left main stem disease in cardiology today.
Read More